Nandrolone Decanoate Injection

Overview of Nandrolone Decanoate Injection

Dosage Strength

200 mg/mL 5 mL Vial (Grapeseed Oil)

General Information

Nandrolone decanoate, sometimes referred to as 19-nortestosterone, is an injectable medicine that is a member of the class II anabolic androgenic steroid subclass (AAS). The medications that belong under class II AAS are all referred to as 19-nortestosterone derivatives; they are all artificial derivatives of the testosterone, a hormone that is produced naturally in males. The main functions of testosterone in males are to promote the development of secondary sexual characteristics (androgenic effects) during puberty and to promote the growth and maintenance of muscle mass (anabolic effects). As a result, drugs that fall into the AAS category, like Nandrolone decanoate, were synthesized to have more anabolic and fewer androgenic properties. 1

Nandrolone was first created and reported by Birch in 1950, and it shares many chemical properties with testosterone. The absence of a methyl group at carbon C-19 in nandrolone is the only difference between testosterone and nandrolone’s chemical makeup. Nandrolone decanoate has very powerful anabolic effects that are substantially stronger than those of testosterone, but it has minimal androgenic effects because of its demethylation at C-19. 2

One of the primary uses for injectable nandrolone decanoate in medicine is the care of refractory anemia that is unresponsive to other forms of therapy. Nandrolone stimulates the kidneys to produce erythropoietin, which increases the bulk and volume of red blood cells. Additionally, nandrolone may support tissue growth and the ensuing development of muscular mass in patients with chronic wasting disorders like cancer. The medical treatment of postmenopausal women with osteoporosis may potentially involve the use of nandrolone. 34


1.Kishner, S., Morello, J.K., “Anabolic Steroid Use and Abuse”, Medscape: Endocrinology. October 2017. Retrieved from
2.Patane, F.G., Liberto, A., Maglitto, A.N.M., Malandrino, P., Esposito, M., Amico, F., Cocimano, G., Li Rossi, G., Condorelli, D., Di Nunno, N., Montana, A., “Nandrolone Decanoate: Use, Abuse and Side Effects”, Medicina (Kaunas), vol. 56 issue 11. November 2020. Available:
3.Geusens, P.,” Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis”. Clinical Rheumatology suppl. 3, pp. 32-39. Available:,patients%20with%20corticosteroid%20induced%20osteoporosis.
4.Nandrolonr Decanoate. Available:
5.Nandrolone Decanoate, Drug Bank. Available:
6.Nandrolone Decanoate, PubChem. National Library of Medicine. Available:
7.Ayotte, C. , “Significance of 19-norandrosterone in athletes’ urine samples”, British Journal of Sports Medicine, vol.40 supp.1, i25-129. July 2006. Available:
8.Nandrolone Decanoate. Available:
9.Grossmann, M., Davey, R.A., “Androgen Receptor Structure, Function and Biology: From Bench to Bedside”, Clinical Biochemist Reviews, vol.37 issue 1, pp. 3 – 15. Available:
10.Bagchus, W.M., Smeets, J.M.W., Verheul, H.A.M., Jager-Van Der Veen, S.M., Port, A., Geurts, T.B.P., “Pharmacokinetic Evaluation of Three Different Intramuscular Doses of Nandrolone Decanoate: Analysis of Serum and Urine Samples in Healthy Men”, The Journal of Clinical Endocrinology & Metabolism”, vol.90 issue 5, pp.2624 – 2630. Available:
11.A. Daiber, L. Herveé, I. Con, A. Donoso, “Treatment of Aplastic Anemia with Nandrolone Decanoate”, Blood, vol. 36 issue 6, pp. 748 – 753.
12.Ballal, S.H., Domoto, D.T., Polack, D.C., Marciulonis, P., Martin, K.J., “Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease”, American Journal of Kidney Disease, vol.17 issue 1, pp.29-33. January 1991.
13.Barton, A.P., Chretien, C., Lau, A.H.,” The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients”, Clinical Nephrology, Vol.58 issue 1, pp.38-46. July 2002.
14.Johansen, K.L., Mulligan K, Schambelan M., “Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis: A Randomized Controlled Trial”. JAMA. Vol. 281 issue 14, pp. 1275-1281. April 1999.
15.Frisoli, A. Chaves, P.H.M., Pinheiro, M.M., Szejnfeld, V.L., “The Effect of Nandrolone Decanoate on Bone Mineral Density, Muscle Mass, and Hemoglobin Levels in Elderly Women With Osteoporosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial”, Journal of Gerontology: Medical Sciences, vol.60A issue 5, pp. 648-653. 2005.
16.Basaria, S., Wahlstrom, J.T., Dobs, A.S.,” Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases”, The Journal of Clinical Endocrinology & metabolism, vol. 86 issue 11, pp.5108-5117. November 2001.
17.Nandrolone Decanoate Injection, USP. Available:
18.Nandrolone Pregnancy and Breastfeeding Warnings. Available:
19.Wells PS, Holbrook AM, Crowther NR et al. Interaction of warfarin with drugs and food. Ann Intern Med 1994;121:676—83.
20.Propecia® (finasteride) package insert. Whitehouse Station, NJ: Merck & Co., INC.; 2003 Oct.
21.Avodart™ (dutasteride) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005 May.
22.Robbers JE, Tyler VE. Tyler’s Herbs of Choice: the Therapeutic Use of Phytomedicinals. Binghamton NY: Haworth Herbal Press, Inc.; 1999.
23.German Commission E. Saw Palmetto berry, Sabal fructus, monograph Published March 2, 1989 and revised January 17, 1991. In: Blumenthal, M et al ., eds. The complete German Commission E Monographs -Therapeutic Guide to Alternative Medicines. Boston MA: Int
24.Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity, and partial androgen deficiency. Aging Male 2003;6:1—7.
25.Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity, and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Clin Endocrinol 2006; 154:899—906.
26.Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. J Clin Endocrinol Metab 1996; 81:1582—5.
27.Corrales JJ, Burgo RM, Garcia-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004;53:666—72.
28.Lee CH, Kuo SW, Hung YJ, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocrine Res 2005;31:139—148.
29.Goffin E, Pirson Y, Geubel A, et al. Cyclosporine-methyltestosterone interaction. Nephron 1991;59:174—5.
30.Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, et al. Possible cyclosporin-danazol interaction in a patient with aplastic anaemia. Am J Hematol 1999;62:63—4.
31.Moller BB, Ekelund B. Toxicity of cyclosporine during treatment with androgens. N Engl J Med 1985;313:1416.
32.Ross WB, Roberts D, Griffin PJ, et al. Cyclosporin interaction with danazol and norethisterone. Lancet 1986;1:330.
33.Florinef® Acetate (fludrocortisone acetate) package insert. Bristol, TN: Monarch Pharmaceuticals; 2003 Jul.
34.Humatrope™ (somatropin);package insert. Indianapolis, IN: Eli Lilly and Company; 2003 Jul.
35.Zoladex® (goserelin acetate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2003 Dec.
36.Viadur® (leuprolide implant) package insert. Westhaven, CT: Bayer Pharmaceuticals; 2002 May.
37.Aldercreutz H, Mazur W. Phyto-estrogens and western diseases. Annals of Medicine 1997;29:95—120.
38.Nandrolone Side Effects. Available:

Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.